Our study employed comprehensive genetic and pharmacological screenings to identify LSD1 as a promising synthetic lethal target in combination with proteasome inhibitors (PIs) in multiple myeloma (MM) and other B-cell malignancies. The gene discussed is KDM1A; the disease is AL amyloidosis.